Jazz Pharmaceuticals plc
JAZZ · Price history
Price at last available close
$206.78
−$31.50 (-13.22%) 1M
2026-10-27
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Jazz Pharmaceuticals plc
Primary reporting period: 2025-12-31 · Research updated Oct 12, 2026. A research update is not a new financial filing.
Who they are
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia.
How they make money
Jazz Pharmaceuticals operates a specialty biopharmaceutical business model focused on identifying, developing, and commercializing differentiated therapies for rare diseases. The company generates revenue primarily through the sale of its proprietary pharmaceutical products and, to a lesser extent, through royalties and contract revenues from licensed assets.
Products & services
The company's portfolio includes therapies for rare diseases in neuroscience and oncology, such as Epidiolex/Epidyolex for epilepsy, and various oxybate-based products for sleep disorders.
Brands & revenue mix
A cannabinoid-based medicine for the treatment of seizures associated with rare forms of epilepsy.
Separate brand revenue is not available in this research.Source
A medication for the treatment of cataplexy or excessive daytime sleepiness in patients with narcolepsy.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Calculated from reported segment revenue. Check the source period and revenue basis before comparing shares. Categories can overlap and may not add to 100%.
Geographic revenue
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Calculated from reported segment revenue. Check the source period and revenue basis before comparing shares. Categories can overlap and may not add to 100%.
Customer concentration
The company discloses that it is subject to customer concentration risks due to its reliance on a limited number of specialty distributors and pharmacies for the distribution of its products, as noted in the 2025 10-K.
Suppliers, materials & equipment
- Contract Manufacturing Organizations — The company relies on third-party contract manufacturers for the production of its drug substances and finished products; specific supplier names are not disclosed.Source
Strengths
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
47
Weak
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
63
Fair
Financial Strength
70
Business Quality / Moat
76
Management
76
Growth Quality
38
Risk / Durability
23
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
58
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
61/100
Building Historical Record
Model Score 61/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
At today’s price, the WSS valuation framework currently reads as moderate rather than unusually attractive.
The model outlook is currently moderate.
- •Balance-sheet / debt profile scores strongly
- •Recent buyback activity is present
- •Debt service risk
- •M&A headline · Sep 18, 2026
- •M&A headline · Sep 15, 2026
- •Revenue fundamentals are weak
- •Asset quality is a weaker factor
Company-specific research
Questions worth answering for JAZZ
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can JAZZ maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •Is JAZZ's positive free cash flow repeatable, or is the current level being helped by temporary working-capital or spending changes?
- •Is JAZZ's debt load manageable relative to cash generation, interest costs and upcoming maturities?
Essential Investment Snapshot
Wall Street Score
47
Opportunity Score
58
Market Cap
$13.42B
P/E Ratio
15.2
EPS
$15.20
52-Week High
$266.38
52-Week Low
$128.80
Beta
0.32
Intrinsic Value
$289.07
Analyst Target
$300.00
Shares Outstanding
61.0M
Total Revenue
$4.60B
Total Debt
$4.41B
Dividend
No current dividend
Liquidation Value / Share
$78.74
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Strong downward momentum
Low movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for JAZZ
Detected from reported data — verify before acting.Historical repurchase activity
Reported cash flows or share-count measures indicate past repurchase activity. This does not verify an active buyback authorization or future purchases.
Debt service risk
Interest coverage is low (~1.2x). Earnings may be strained to cover interest expense.
M&A headline · Sep 18, 2026
Should You Buy Jazz Pharmaceuticals Stock After Its Actio Acquisition? — This is a provider-linked headline, not an independently confirmed event. Check the article and company filings for the subject, proposed/completed status, and subsequent updates.
The Motley FoolM&A headline · Sep 15, 2026
Jazz Pharmaceuticals Completes Acquisition of Actio Biosciences — This is a provider-linked headline, not an independently confirmed event. Check the article and company filings for the subject, proposed/completed status, and subsequent updates.
PRNewsWireCommunity Sentiment
0 active · 0 total callsNo personal call yet on JAZZ.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Portfolio of differentiated therapies for rare diseases.
- +Efficient commercialization model for concentrated patient populations.
- +Positive free cash flow may provide capacity to invest in growth.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Biotechnology industry.
- −Generic competition for key products.
- −Reliance on third-party manufacturers and supply chain stability.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
2 historical score records availablePrevious Score
27
Jul 24, 2026
Change
+20.0
points
Current Score
47
Oct 1, 2026
Category Changes
JAZZ increased 20 points because Revenue improved by 18.4 points, Capital improved by 39 points, Management improved by 53.1 points.
Positive Contributors
- + Revenue improved by 18.4 points
- + Capital improved by 39 points
- + Management improved by 53.1 points
- + Valuation improved by 57.2 points
- + Buffett improved by 17.7 points
Projected Score
Projected Score
51
Projected Change
+4.4 points
Preliminary comparable-period financial changes suggest improvement of approximately 4.4 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
UndervaluedCurrent Price
$206.78
Model Intrinsic Value
$289.07
Difference
−$82.29
-28.5% vs IV
Margin of Safety
28.5%
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.60B | $4.27B | $4.07B | $3.83B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $705.2M | $503.3M | $445.7M | $435.6M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | $3.90B | $3.76B | $3.62B | $3.40B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $753.7M | $782.7M | $884.0M | $849.7M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $1.68B | $1.81B | $1.39B | $1.34B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $2.47B | $3.54B | $2.91B | $2.82B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | $1.48B | $108.5M | $1.52B | $1.45B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | $1.43B | $224.4M | $716.6M | $578.6M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $194.4M | $195.1M | $238.1M | $289.4M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | $727.5M | -$628.6M | $468.7M | $294.9M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | -$213.3M | -$272.4M | -$91.4M | -$119.9M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | $940.8M | -$356.1M | $560.1M | $414.8M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $15.20 | $-5.84 | $9.06 | $6.55 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 63.20M | 60.98M | 61.84M | 63.29M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 69.40M | 60.98M | 66.01M | 72.07M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$1.21B
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
$2.78
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
-18.8%
Cash Change
+36.1%
Margin Change
+84.7 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Margins expanded
- Cash position grew
- Debt reduced
Potential Score Impact
Positive indicators included revenue growth, cash levels, debt levels, net income margin. Pressure indicators included EPS growth. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue increased 15.5%. EPS declined 123.7%. Cash increased 36.1%. Total debt declined 18.8%. Net income margin improved by 84.7 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
10
Smart Money
10
Number of Gurus
1
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
2 historical records2 historical score records available.
Historical Score Chart
2 of 2 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
BiotechnologyNews
Analysts Estimate Jazz Pharmaceuticals (JAZZ) to Report a Decline in Earnings: What to Look Out for
Ziihera® (zanidatamab-hrii) Combinations Demonstrate Sustained Survival at Three Years in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma at ESMO 2026
Is JAZZ Stock Still a Smart Way to Play Medical Cannabis?
Jazz Pharmaceuticals: Ziihera And Portfolio Diversification Are Changing The Earnings Story
Rumor Mill · JAZZ
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial